Abstract
Autoimmune responses can arise because the repertoire of both T- and B-cell receptors, which allows recognition of pathogens, may contain receptors recognizing self-components. Ideally, autoreactive lymphocytes should be destroyed in the thymus during negative selection and induction of autoimmunity should be controlled. However, a great number of self-reactive lymphocytes escape thymic negative selection processes and form a peripheral pool of potentially autoimmune disease-mediating lymphocytes. On the other hand, self-tissues and -cells are routinely destroyed in our body and thus self-antigens are available in situ. If self-reactive lymphocytes are not completely destroyed in thymus by negative selection, autoantigens may activate these lymphocytes, and the feature of autoimmunity is developed. Thus, the autoimmune process is a normal phenomenon of living organisms. To block the activities of these autoreactive lymphocytes and minimize clinically apparent autoimmune diseases, another mechanism is active in situ. A population of tolerogenic immunocytes (T-regulatory cells) is present in our body. When these lymphocytes also fail to block progression of an autoimmune process, the pathological consequences of autoimmunity become manifest. It is therefore important to clarify the mechanisms leading to the initial activation of self-reactive lymphocytes that induce and sustain the autoimmune response. Also, insights are required regarding the causes underlying the inability of tissue-derived dendritic cells (DCs) to induce immune tolerance to self-antigens. In addition, another population of DCs, called regulatory DCs, should downregulate the autoimmune processes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Recommended Readings
Feili-Hariri M, Flores RR, Vasquez AC, Morel PA (2006) Dendritic cell immunotherapy for autoimmune diabetes. Immunol Res 36:167–173
Hardin JA (2005) Dendritic cells: potential triggers of autoimmunity and targets for therapy. Ann Rheum Dis 64(suppl) 4:86–90
Kuwana M (2002) Induction of anergic and regulatory T cell by plasmacytoid dendritic cells and other dendritic cell subsets. Hum Immunol 63:1156–1163
Ludewig B, Krebs P, Junt T, et al (2003) Dendritic cell homeostasis in the regulation of self-reactivity. Curr Pharm Design 9:221–231
Manuel SL, Rahman S, Wigdahl B, Khan ZK, Jain P (2007) Dendritic cells in autoimmune diseases and neuroinflammatory disorders. Front Biosci 12:4315–4335
Mehling A, Beissert S (2003) Dendritic cells under investigation in autoimmune disesases. Crit Rev Biochem Mol Biol 38:1–21
Penna G, Giarratana N, Amuchastegui S, Mariani R, Daniel KC, Adorini L (2005) Manipulating dendritic cells to induce regulatory T cells. Microbes Infect 7:1033–1039
Tarner IH, Fathman CG (2006) Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease? Nat Clin Pract Rheumatol 2:491–499
Thomson AG, Thomas R (2002) Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol 80:509–519
Xiao BG, Huang YM, Link H (2006) Tolerogenic dendritic cells: the ins and outs of outcome. J Immunother 29:465–471
Rights and permissions
Copyright information
© 2008 Morikazu Onji and Sk. Md. Fazle Akbar
About this chapter
Cite this chapter
(2008). Dendritic Cells and Autoimmunity. In: Dendritic Cells in Clinics. Springer, Tokyo. https://doi.org/10.1007/978-4-431-79466-0_5
Download citation
DOI: https://doi.org/10.1007/978-4-431-79466-0_5
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-79465-3
Online ISBN: 978-4-431-79466-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)